Malaria vaccine2 Oct 2023 18:17
A highly effective malaria vaccine has been recommended for widespread use by the World Health Organization.
The R21/Matrix-M vaccine, developed by the University of Oxford, is only the second malaria vaccine to be recommended by the WHO. It is the first to meet the WHO’s target of 75% efficacy. Malaria, a mosquito-borne disease, claims half a million lives every year and mostly affects children under the age of five, and pregnant women. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” said Dr Tedros Adhanom Ghebreyesus, director general of the WHO. Demand for vaccines is huge. However, available supplies of the RTS,S vaccine, the first malaria vaccine approved by the WHO in 2021, are limited. A second WHO-recommended vaccine is expected “to protect more children faster, and to bring us closer to our vision of a malaria-free future,” said Tedros.
The RTS,S vaccine will be available in some African countries in early 2024 and the R21 malaria vaccine is expected to become available to countries in mid-2024. The world’s largest vaccine manufacturer by doses – the Serum Institute of India – is already lined up to make more than 100m doses a year and plans to scale up to 200m a year, the BBC reported. Each dose costs between $2 and $4; four doses are needed per person. That is about half the price of RTS,S. So far, there are only 18m doses of RTS,S. (Guardian)